Two Sigma Advisers
CMPX icon

Two Sigma Advisers’s Compass Therapeutics CMPX Stock Holding History

Two Sigma Advisers’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,200
Closed -$81.6K – 454
2025
Q4 		$81.6K Buy
+15,200
New +$70.2K ﹤0.01% 2251
2025
Q1 		– Sell
-51,000
Closed -$74K – 2411
2024
Q4 		$74K Sell
51,000
-35,400
-41% -$58.8K ﹤0.01% 2255
2024
Q3 		$159K Sell
86,400
-27,400
-24% -$34.2K ﹤0.01% 2115
2024
Q2 		$114K Buy
113,800
+54,500
+92% +$79.6K ﹤0.01% 2307
2024
Q1 		$117K Sell
59,300
-11,500
-16% -$19.9K ﹤0.01% 2287
2023
Q4 		$110K Buy
70,800
+32,200
+83% +$55.7K ﹤0.01% 2318
2023
Q3 		$76K Buy
+38,600
New +$95.4K ﹤0.01% 2241

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Advisers's CMPX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Compass Therapeutics (CMPX) in Q1 2026, closing a stake of 15,200 shares — an estimated $81.6K sold.

Two Sigma Advisers first reported a position in CMPX in Q3 2023 and held it in 7 quarters. The position peaked at $159K in Q3 2024. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Compass Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 15,200 Compass Therapeutics shares in Q1 2026, an estimated $81.6K.
  • Two Sigma Advisers first reported a position in Compass Therapeutics in Q3 2023 and held it in 7 quarters.
  • Two Sigma Advisers's Compass Therapeutics position peaked at $159K in Q3 2024.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.